473PPhase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
ConclusionsLapatinib and trametinib could be combined in an intermittent dosing schedule with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed with sufficient target engagement.Clinical trial identificationNCT02230553.Legal entity responsible for the studyThe Netherlands Cancer Institute.FundingNovartis.DisclosureN. Steeghs: Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Bristol-Meyers Squibb; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): AB Science; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck Sharp& Dohme; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Merus; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Incyte. K. Monkhorst: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert te...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Grants | HER2 | Legislation | Lung Cancer | Merck | Netherlands Health | Non-Small Cell Lung Cancer | Oral Cancer | Pancreas | Pancreatic Cancer | Pfizer | Science | Study | Toxicology